Medidata Solutions, Inc. (NASDAQ:MDSO)‘s stock had its “buy” rating reaffirmed by analysts at KeyCorp in a report issued on Sunday. They currently have a $86.00 target price on the stock. KeyCorp’s price target would suggest a potential upside of 13.38% from the company’s previous close.

MDSO has been the subject of a number of other research reports. Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Friday, July 21st. Citigroup Inc. reiterated a “buy” rating and set a $95.00 price target (up previously from $94.00) on shares of Medidata Solutions in a research report on Monday, July 24th. SunTrust Banks, Inc. boosted their price target on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Morgan Stanley boosted their price target on Medidata Solutions from $74.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, July 20th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $78.00 price target on shares of Medidata Solutions in a research report on Tuesday, August 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Medidata Solutions has an average rating of “Buy” and an average price target of $84.00.

Medidata Solutions (MDSO) opened at 75.85 on Friday. The stock has a market cap of $4.29 billion, a PE ratio of 122.54 and a beta of 1.81. Medidata Solutions has a 52-week low of $46.10 and a 52-week high of $85.92. The firm has a 50-day moving average price of $74.64 and a 200 day moving average price of $70.19.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The business had revenue of $137.41 million during the quarter, compared to analyst estimates of $134.28 million. During the same quarter in the previous year, the firm posted $0.24 EPS. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. Equities analysts anticipate that Medidata Solutions will post $1.28 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions, Inc. (MDSO) Rating Reiterated by KeyCorp” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/19/medidata-solutions-inc-mdso-rating-reiterated-by-keycorp.html.

In other news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.80% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after buying an additional 208 shares in the last quarter. Parametrica Management Ltd bought a new stake in shares of Medidata Solutions in the 2nd quarter worth $216,000. Cubist Systematic Strategies LLC bought a new stake in shares of Medidata Solutions in the 2nd quarter worth $227,000. ETF Managers Group LLC bought a new stake in shares of Medidata Solutions in the 2nd quarter worth $233,000. Finally, LS Investment Advisors LLC raised its stake in shares of Medidata Solutions by 44.6% in the 1st quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock worth $191,000 after buying an additional 1,021 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.